Proton Beam Therapy Improves Local Control in Liver CancerProton Beam Therapy Improves Local Control in Liver Cancer
High-dose, hypofractionated proton beam therapy provides excellent local control for patients with localized, unresectable hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC), according to results of a phase 2 study. Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 23, 2015 Category: Radiology Tags: Hematology-Oncology News Source Type: news
MACC1 gene is an independent prognostic biomarker for survival in Klatskin tumor patients
(Max Delbrück Center for Molecular Medicine in the Helmholtz Association) Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment is best for patients with Klatskin carcinoma, one type of bile duct cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 31, 2015 Category: Biology Source Type: news
Asbestos Puts Shipbreaking Workers at Risk for Many Cancers
This study was one of the few that involved only "shipbreaking," which is the dismantling of old ships for salvage or scrap. It also examined cancers beyond mesothelioma, a cancer caused almost exclusively by inhalation or ingestion of asbestos.
The study, published in the on-line medical journal PLOS One, was linked to the Taiwan Cancer Registry and involved 4,227 workers from the 1985 Kaohsiung Shipbreaking Workers Union who belonged to the Labor Insurance Program.
They were followed until 2008. There were 940 deaths and 436 cancer cases reported. Their numbers were compared to a control group of 22,135 who worked elsewh...
Source: Asbestos and Mesothelioma News - August 4, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news
SWOG Trial Defines a Regimen for Biliary CancerSWOG Trial Defines a Regimen for Biliary Cancer
Adjuvant capecitabine and gemcitabine followed by radiotherapy and capecitabine was well tolerated and effective in the treatment of extrahepatic cholangiocarcinoma and gallbladder carcinoma. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 27, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Delcath’s melphalan gets FDA orphan drug status to treat cholangiocarcinoma
Specialty pharmaceutical firm Delcath Systems has obtained orphan drug status from the US Food and Drug Administration (FDA) for its melphalan to treat cholangiocarcinoma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 20, 2015 Category: Pharmaceuticals Source Type: news
Delcath wins FDA nod for Melphalan
Delcath (NSDQ:DCTH) said today it won Orphan Drug Designation from the FDA for melphalan, used in its hepatic delivery system to treat cholangiocarcinoma.
Orphan drug designations are bestowed by the FDA on treatments for “orphan diseases”, usually defined as conditions that affect fewer than 200,000 people nationwide. The designation comes with benefits, such as tax credits, exclusivity and a waived New Drug Application user fee.
The drug is at the heart of Delcath’s hepatic delivery system, a chemotherapy system that delivers the melphalan to a patients liver to treat intrahepatic cholangiocarcinoma,...
Source: Mass Device - July 20, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Drug Pumps Food & Drug Administration (FDA) Regulatory/Compliance Delcath Systems Inc. Source Type: news
The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants
Scientists to Investigate Improved Treatments and a Cure for Rare Disease – Bile Duct Cancer(PRWeb May 30, 2015)Read the full story at http://www.prweb.com/releases/Cholangiocarcinoma/05/prweb12756957.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 30, 2015 Category: Pharmaceuticals Source Type: news
Bile duct cancer study may pave way for new treatments
(University of Edinburgh) Patients with bile duct cancer could be helped by a new class of experimental drug, a laboratory study led by the University of Edinburgh has shown. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 17, 2015 Category: Cancer & Oncology Source Type: news
Biochemically modified constituent of yew demonstrates early effectiveness in bile duct cancer
Bile duct cancers are amongst the most aggressive tumor-related diseases and, so far, the medical treatment options available have been limited. Clinical oncologists have now demonstrated that the substance nab-paclitaxel, a biochemically modified ingredient that occurs in the bark of the Pacific yew tree, could be highly effective against bile duct cancers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 13, 2015 Category: Science Source Type: news
Rare cancer's genetic pathway identified by scientists
The 'mutational landscape' of intrahepatic cholangiocarcinoma, a rare, highly fatal form of liver cancer that disproportionately affects people in Asian countries, has been identified by an international team of researchers. The findings could potentially lead to earlier and more accurate diagnosis and increased survival rates for patients with the disease, also known as intrahepatic bile duct cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 25, 2014 Category: Science Source Type: news
Scientists identify rare cancer's genetic pathway
(Simon Fraser University) An international research team, including four Simon Fraser University scientists, has identified the 'mutational landscape' of intrahepatic cholangiocarcinoma, a rare, highly fatal form of liver cancer that disproportionately affects people in Asian countries. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 24, 2014 Category: Cancer & Oncology Source Type: news
Woman's genes give clue for unique liver cancer treatment
A 47-year-old American woman with intrahepatic cholangiocarcinoma (ICC) is the first person with her condition to receive a uniquely personalized treatment based on her genetic profile. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 6, 2014 Category: Science Source Type: news
Woman's genes give clue for unique liver cancer treatment
(ecancermedicalscience) A 47-year-old American woman with intrahepatic cholangiocarcinoma is the first person with her condition to receive a uniquely personalized treatment based on her genetic profile.'Using the information from the genetic makeup of our patient's cancer, we were able to formulate a personalized treatment,' says Dr. Arturo Loaiza-Bonilla of the University of Pennsylvania, lead author of the case report published in ecancermedicalscience. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 6, 2014 Category: Cancer & Oncology Source Type: news
Immunotherapy Trials May Result in Breakthrough Mesothelioma Treatment
Melinda Bachini thought she was spending quality time with family and friends on her son's 14th birthday.
Instead, doctors in 2009 diagnosed the mother of six with a rare, incurable bile duct cancer in its final stage. Options were slim, and her prognosis grim.
Hope seemed lost after surgery and chemotherapy failed her, but in 2012 she enrolled in a clinical trial at the National Institutes of Health involving an immunotherapy called adoptive cell transfer (ACT). In the simplest terms, it uses patients' immune system T cells to fight their cancer — and it appears to be working.
Although she continues with regular chec...
Source: Asbestos and Mesothelioma News - October 9, 2014 Category: Environmental Health Authors: Michelle Whitmer Tags: Research & Clinical Trials Source Type: news
Researchers unlock genetic code of cancer-causing liver fluke parasite
The genetic code of the liver fluke parasite, Opisthorchis viverrini, has been cracked by an international team of researchers using a unique DNA analysis technique. Opisthorchis viverrini is a trematode that infects millions in Asia, and is a significant risk factor for Cholangiocarcinoma (CCA) or bile duct cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 10, 2014 Category: Science Source Type: news
